RxSight

Q2 FY2026 EarningsQ2 FY2026 beat consensus on both top and bottom lines, with revenue of $33.7M vs. $32.5M expected and adjusted EPS of -$0.11 vs. -$0.19 expected. The revenue beat was primarily driven by the recognition of $6.5M from the Alcon strategic collaboration, masking a 19% YoY decline in product sales due to competitive trialing. Gross margin of 76.7% exceeded the 72.75% consensus, bolstered by high-margin collaboration revenue. However, management withdrew all 2026 guidance following the appointment of a new CEO, introducing significant near-term uncertainty despite the strategic Alcon partnership.